Holen Sie sich die Stockscreener-App
13.48
2.21%
-0.315
Schlusskurs vom Vortag:
$13.80
Offen:
$13.84
24-Stunden-Volumen:
426.02K
Relative Volume:
0.64
Marktkapitalisierung:
$814.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.99M
KGV:
-6.3023
EPS:
-2.1397
Netto-Cashflow:
$-79.92M
1W Leistung:
-2.71%
1M Leistung:
+20.38%
6M Leistung:
-35.65%
1J Leistung:
-27.99%
1-Tages-Spanne:
$13.02
$13.84
1-Wochen-Bereich:
$13.02
$14.35
52-Wochen-Spanne:
$10.52
$34.48
Oculis Holding Ag Stock (OCS) Company Profile
Firmenname
Oculis Holding Ag
Sektor
Branche
Telefon
-
Adresse
-
Compare OCS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
13.48 | 833.36M | 0 | -117.99M | -79.92M | -2.1397 |
VRTX
Vertex Pharmaceuticals Inc
|
522.41 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.94 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.98 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.29 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.97 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Eingeleitet | JP Morgan | Overweight |
| 2025-08-27 | Eingeleitet | Needham | Buy |
| 2023-12-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-10-05 | Eingeleitet | Stifel | Buy |
| 2023-06-14 | Eingeleitet | BofA Securities | Buy |
| 2023-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-06-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-10 | Eingeleitet | Pareto | Buy |
| 2023-04-28 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Oculis Holding Ag Aktie (OCS) Neueste Nachrichten
Oculis Holding AG Warrants 2023-06.03.28 on OCULIS HOLDING Financial Disclosures & SEC Filings - TradingView
Oculis stock gains after FDA trial design agreement - Investing.com
Oculis to present updates on late-stage eye dis... - Pluang
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - The Manila Times
Oculis to Present Late-Stage Pipeline Update at Piper Sandler Virtual Ophthalmology Conference - Quiver Quantitative
Oculis spotlights late-stage eye drugs at Piper Sandler event - Stock Titan
Trading the Move, Not the Narrative: (OCS) Edition - Stock Traders Daily
Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway - TipRanks
Oculis Holding AG Actuals & Estimates (NASDAQ:OCS) - TradingView
Oculis Holding AG Warrants (OCSAW) See Upward Momentum Amid Modest GainsSign of Strength - dars.gov.et
Oculis (NASDAQ: OCS) details late-stage eye drugs and cash runway into 2029 - Stock Titan
OCS Forecast — Price Target — Prediction for 2027 - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AGOCS - PR Newswire
OCSOculis Holding AG Revenue Breakdown - Finviz
Oculis Holding AG (OCSAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
(OCS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Oculis Holding AG (OCS) Institutional Confidence - TradingKey
Oculis Holding AG (OCS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oculis Holding AG (OCS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oculis Holding AG (OCS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oculis Holding AG (OCS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OCS News | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill
Oculis Holding AG (OCS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oculis Holding AG (OCS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oculis Holding AG (OCS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oculis Holding AG (OCSAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oculis Holding AG (OCSAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oculis Holding AG (OCSAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oculis Holding AG (OCSAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oculis Holding AG (OCSAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oculis Holding AG (OCSAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oculis Holding AG (OCSAW) Institutional Confidence - TradingKey
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm - GlobeNewswire
Oculis : Minutes of the 2026 Annual General Meeting of Shareholders - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Oculis Holding AG (OCS) And Encourages Shareholders to Connect - ACCESS Newswire
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment - Streetwise Reports
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles - AOL.com
Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Oculis shelves FDA filing after phase 3 DME trials miss key vision goals - MSN
Oculis enrolls first patient in licaminlimab PREDICT-1 DED trial - Optometry Times
Oculis to present neuroprotective drug Privosegtor at Clinical Trials Summit 2026 - Pluang
Oculis to present Privosegtor's progress for optic neuritis treatment at Clinical Trials Summit 2026 - Pluang
Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud I - GuruFocus
H.C. Wainwright reiterates Oculis stock rating on trial start - Investing.com UK
H.C. Wainwright reiterates Oculis stock rating on trial start By Investing.com - Investing.com Australia
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - The Manila Times
Oculis Holding AG to Present on Privosegtor at Clinical Trials at the Summit 2026 - Quiver Quantitative
Finanzdaten der Oculis Holding Ag-Aktie (OCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
3.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):